Modified T-Cells in Treating Patients With Epstein-Barr Virus Positive Lymphoma.

Inclusion Criteria

• INCLUSION CRITERIA AT TIME OF PROCUREMENT:
• Any patient, regardless of age or sex, with EBV-positive Hodgkin’s or non-Hodgkin’s lymphoma, (regardless of the histological subtype) or EBV (associated)-T/NK-lymphoproliferative disease or severe chronic active EBV (CAEBV) * In second or subsequent relapse (or first relapse or with active disease if immunosuppressive chemotherapy contraindicated or multiply relapsed patients in remission who have a high risk of relapse) or any patient with primary disease or in first remission if immunosuppressive chemotherapy is contraindicated, e.g. patients who develop Hodgkin disease after solid organ transplantation or if the lymphoma is a second malignancy e.g. a Richter’s transformation of chronic lymphocytic leukemia (CLL) (Group A) OR * In remission or with minimal residual disease status after autologous or syngeneic stem cell transplantation (SCT) (Group B) ** CAEBV is defined as patients with high EBV viral load in plasma or peripheral blood mononuclear cells (PBMC) (> 4000 genomes per ug PBMC deoxyribonucleic acid [DNA]) and/or biopsy tissue positive for EBV
• EBV positive tumor (can be pending)
• Weighs at least 12kg
• Informed consent explained to, understood by and signed by patient/guardian; patient/guardian given copy of informed consent
• INCLUSION CRITERIA AT TIME OF INFUSION:
• Any patient, regardless of age or sex, with EBV-positive Hodgkin’s or non-Hodgkin’s lymphoma (regardless of histologic subtype), or EBV (associated)-T/NK-lymphoproliferative disease or severe chronic active EBV (CAEBV) and; in second or subsequent relapse (or first relapse or with active disease if immunosuppressive chemotherapy contraindicated or multiply relapsed patients in remission who have a high risk of relapse) OR any patient with primary disease or in first remission if immunosuppressive chemotherapy is contraindicated, e.g. patients who develop Hodgkin disease after solid organ transplantation or if the lymphoma is a second malignancy e.g. a Richter’s transformation of CLL (Group A); Patients with relapsed or refractory lymphoma that are eligible for a stem cell transplant will not be treated on this study as an alternative to transplant; OR in remission or with minimal residual disease status after autologous or syngeneic SCT (Group B) * CAEBV is defined as patients with high EBV viral load in plasma or PBMC (> 4000 genomes per ug PBMC DNA) and/or biopsy tissue positive for EBV
• EBV positive tumor
• Patients with life expectancy >= 6 weeks
• Bilirubin =< 3 x upper limit of normal
• Aspartate aminotransferase (AST) =< 5 x upper limit of normal
• Hemoglobin (Hgb) > 8.0 (may be a transfused value)
• Creatinine =< 2 x upper limit of normal for age
• Pulse oximetry of > 90% on room air
• Patients should have been off other investigational therapy for 4 weeks prior to entry in this study
• Patients with a Karnofsky/Lansky score of >= 50
• Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded; the male partner should use a condom
• Informed consent explained to, understood and signed by patient/guardian; patient/guardian given copy of informed consent

Exclusion Criteria

• EXCLUSION CRITERIA AT TIME OF PROCUREMENT:
• Active infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV) (can be pending at this time)
• EXCLUSION CRITERIA AT TIME OF INFUSION:
• Pregnant or lactating
• Severe intercurrent infection
• Current use of systemic corticosteroids > 0.5 mg/kg/day